12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALD-401: Interim Phase II data

Interim data from 10 patients in the double-blind, placebo-controlled, U.S. Phase II RECOVER-Stroke trial showed that an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke was safe with no severe adverse events reported. Data were presented at the...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >